Beta Bionics, Inc. (BBNX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 0 | 12 | 65 | 100 | 119 | 127 |
| Operating profit | $m | -72 | -83 | ||||||
| Net profit | $m | - | - | -65 | -44 | -55 | -73 | -73 | -84 |
| EPS reported | $ | -1.81 | -1.68 | ||||||
| Operating cashflow per share | $ | -1.26 | -1.25 | ||||||
| Capex per share | $ | 0.13 | 0.13 | ||||||
| FCF per share | $ | -1.39 | -1.38 | ||||||
| Free cash flow | $m | -56 | -61 | ||||||
| Net debt | $m | -219 | -180 | ||||||
| Book value equity | $m | 288 | 256 | ||||||
| Book value per share | $ | 7.10 | 5.76 | ||||||
| Number of shares | m | 40.53 | 44.55 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 4.29 | 4.82 | ||||||
| P/S LTM | x | 12.32 | 10.38 | ||||||
| P/FCF LTM | x | -21.97 | -20.11 | ||||||
| EV/EBITDA LTM | x | -17.22 | -16.88 | ||||||
| EV/Sales LTM | x | 12.08 | 7.02 | ||||||
| Earnings Yield LTM | % | -5.93% | -8.44% | ||||||
| FCF Yield | % | -4.55% | -4.97% | ||||||
| Quality | |||||||||
| ROE | % | -25.45% | -26.30% | ||||||
| ROIC | % | -23.91% | -30.98% | ||||||
| Operating margin | % | -71.50% | -69.75% | ||||||
| Gross margin | % | +55.40% | +58.31% | ||||||
| FCF/Sales | % | -56.08% | -51.60% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +53.94% | +82.75% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -7.70 | -9.43 | ||||||
| Net Debt/EBITDA | x | 0.35 | 0.53 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.76 | -0.70 | ||||||
| Gross debt/equity | x | 0.03 | 0.03 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free